| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c382b2ea086c659f51d8a9ab54a06ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e3a3213a9c1a2d3e4efc922bff5fe0e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-302
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-9065 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-592
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-593
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5082 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-593
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-573 |
| filingDate |
2012-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0126c96077dc77a29811e7e3475fb33e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00919c78fdc8cc330d98e295e04ddee3 |
| publicationDate |
2015-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015224120-A1 |
| titleOfInvention |
Compositions and methods for treating hyperprolinemia-associated mental disorders |
| abstract |
The present invention provides methods for treating or ameliorating the effects of schizophrenia, which include administering to a patient in need thereof a therapeutically effective amount of a proline modulator. Further provided are methods of selecting a patient at risk for or suffering from schizophrenia that is likely to benefit from proline modulation. Methods for identifying an agent that modulates proline levels in a patient and methods for identifying a patient at risk for developing a DTNBP1-related psychiatric illness, as well as other methods and compositions for treating or ameliorating the effects of schizophrenia are also provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10898449-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11648213-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9782395-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11033512-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11337932-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112823004-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017083739-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10179126-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10980753-B2 |
| priorityDate |
2011-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |